락토바실루스 람노서스 GG 관련 항생제 관련 설사(AAD)

Q: Does 락토바실루스 람노서스 GG help with 항생제 관련 설사(AAD)?

Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that 락토바실루스 람노서스 GG may support 항생제 관련 설사(AAD) management. Our evidence grade is A (Strong Evidence).

Q: How much 락토바실루스 람노서스 GG should I take for 항생제 관련 설사(AAD)?

Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of 락토바실루스 람노서스 GG?

Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for 락토바실루스 람노서스 GG and 항생제 관련 설사(AAD)?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.

A 근거 여러 대규모 임상 시험이 일관되게 유의미한 효과를 보여줍니다.

메타분석에서 LGG가 AAD 발생률을 42~49% 감소시키는 것으로 나타났습니다. 항생제 투여 시작 48시간 이내에 시작해 완료 후 7일간 지속하는 것이 가장 효과적입니다.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

결론

Key Study Findings

Observational Study n=279

Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …

Dose: None vs: None Outcome: Probiotic prescribing habits of Italian PCPs 효과: L. rhamnosus GG used by 91.8% None

대상 집단: Italian primary care pediatricians

Other

Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …

Dose: None vs: None Outcome: Clinical guideline recommendations for pediatric GI 효과: None None

대상 집단: Pediatric patients with GI disorders

Controlled Clinical Trial n=24 2 weeks

Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …

Dose: 10^9 CFU/day for 14 days vs: LPS-only group (no probiotics) Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines) 효과: None p<0.05 to <0.001

대상 집단: Male Wistar albino rats with LPS-induced sepsis

Review

The evidence for probiotics in the treatment of digestive disorders in the pediatric population.

Dose: None vs: None Outcome: None 효과: None None

대상 집단: Pediatric population

Randomized Controlled Trial Double-blind

A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …

Dose: Probiotics (multi-strain) vs: Placebo Outcome: Antibiotic-associated diarrhea incidence 효과: None None

대상 집단: Adult patients receiving antibiotics

Review

Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.

Dose: S. boulardii CNCM I-745 vs: Placebo or standard care Outcome: AAD prevention and pediatric gastroenteritis 효과: None None

대상 집단: AAD and gastroenteritis patients (review)

Key Statistics

연구

4000

참여자

↑

Positive

등급

Referenced Papers

The evidence for probiotics in the treatment of digestive disorders in the pediatric population. Review

Journal of gastroenterology … 2025 10 인용

Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in Rats. Other

Medicina (Kaunas, Lithuania) 2025 1 인용

Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. Other

Antibiotics (Basel, Switzerland) 2025

Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. Other

Boletin medico del … 2025

A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea in Adult Patients. Other

Cureus 2024 1 인용

Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. Review

Cureus 2023 19 인용

Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. Review

Archivos argentinos de … 2022 23 인용

Health economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): a cost-effectiveness analysis. RCT

Canadian journal of … 2022 6 인용

Development of enteric polymer-based microspheres by spray-drying for colonic delivery of Lactobacillus rhamnosus GG. Other

International journal of … 2020 32 인용

Risk and Protective Factors for Gastrointestinal Symptoms associated with Antibiotic Treatment in Children: A Population Study. Other

Pediatric gastroenterology, hepatology … 2020 20 인용

Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Review

Pharmacological research 2018 132 인용

A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. Meta-Analysis

BMC gastroenterology 2018 80 인용

Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. Review

United European gastroenterology … 2018 66 인용

Frequency of Antibiotic-Associated Diarrhea and Related Complications in Pediatric Patients Who Underwent Hypospadias Repair: a Comparative Study Using Probiotics vs … RCT

Probiotics and antimicrobial … 2018 26 인용

Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. Review

World journal of … 2017 68 인용

Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. Meta-Analysis

Journal of pediatric … 2016 233 인용

Probiotic Bacterial and Fungal Strains: Claims with Evidence. Review

Digestive diseases (Basel, … 2016 37 인용

The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Systematic Review

Paediatric drugs 2015 122 인용

Probiotics for Prevention and Treatment of Diarrhea. Review

Journal of clinical … 2015 35 인용

Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. Review

Nutrition in clinical … 2015 31 인용

[Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. Review

Nutricion hospitalaria 2015 5 인용

[Effectiveness and safety of probiotics in children on the basis of clinical trials]. Review

Medycyna wieku rozwojowego 2012 1 인용

Probiotics as prevention and treatment for diarrhea. Review

Current opinion in … 2009 82 인용

Probiotics, prebiotics, and synbiotics. Review

Advances in biochemical … 2008 535 인용

Probiotics and prebiotics: effects on diarrhea. Review

The Journal of … 2007 265 인용

Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Meta-Analysis

The American journal … 2006 918 인용

Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. Review

Journal of clinical … 2006 112 인용

Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid. Other

Inflammation 2002 37 인용

Protection from gastrointestinal diseases with the use of probiotics. Review

The American journal … 2001 648 인용

Induction of nitric oxide synthesis by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epithelial cells. Other

Inflammation 2001 101 인용

Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. RCT

The Journal of … 1999 559 인용

Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. RCT

Pediatrics 1999 462 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:: 10-20 billion CFU/day
ibssupport:: 10 billion CFU/day for 4-8 weeks
aadprevention:: 10-20 billion CFU/day (start with antibiotic, continue 7 days after)

상한량: Generally well-tolerated up to 40 billion CFU/day in clinical trials

연구에서 사용된 용량

용량	기간	효과	N
None	--	Mixed	279
None	--	Positive	--
10^9 CFU/day for 14 days	2 weeks	Positive	24
None	--	Mixed	--
Probiotics (multi-strain)	--	Positive	--
S. boulardii CNCM I-745	--	Positive	--
None	--	Positive	--
Twice daily	--	Neutral	2650

권장 복용 시간: On an empty stomach or 30 minutes before meals for optimal survival

Safety & Side Effects

보고된 부작용

⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
⚠ Rare reports of bacteremia in severely immunocompromised individuals
⚠ Occasional loose stools during adjustment period
⚠ Very rare: systemic infection in critically ill patients with central venous catheters

알려진 상호작용

● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
● Antifungals (no known interaction but may affect gut flora balance)

일일 최대 섭취 허용량: Generally well-tolerated up to 40 billion CFU/day in clinical trials

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 락토바실루스 람노서스 GG help with 항생제 관련 설사(AAD)?

Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that 락토바실루스 람노서스 GG may support 항생제 관련 설사(AAD) management. Our evidence grade is A (Strong Evidence).

How much 락토바실루스 람노서스 GG should I take for 항생제 관련 설사(AAD)?

Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of 락토바실루스 람노서스 GG?

Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for 락토바실루스 람노서스 GG and 항생제 관련 설사(AAD)?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.

락토바실루스 람노서스 GG 다른 건강 상태에 대한 근거

과민성 대장 증후군(IBS) B

한눈에 보기

Evidence Strength92%

High confidence

연구 분석

RCT (4)Meta (3)Other (13)

대안 비교

이 건강 상태에 대한 다른 성분의 비교 결과를 확인하세요.

모든 성분 보기: 항생제 관련 설사(AAD)

자세히 알아보기

References

[1] Kok-Ann Gwee et al.. J Gastroenterol Hepatol. 2025. The evidence for probiotics in the treatment of digestive disorders in the pediatric population. doi:10.1111/jgh.16809 PubMed
[2] Necip Gökhan Taş et al.. Medicina (Kaunas). 2025. Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in Rats. doi:10.3390/medicina61040589 PubMed
[3] Giacomo Biasucci et al.. Antibiotics (Basel). 2025. Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care Pediatricians. doi:10.3390/antibiotics14060577 PubMed
[4] Sylvia Cruchet et al.. Bol Med Hosp Infant Mex. 2025. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. doi:10.24875/BMHIM.M25000043 PubMed
[5] Jamal Shah et al.. Cureus. 2024. A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea in Adult Patients. doi:10.7759/cureus.70881 PubMed
[6] Sarath Gopalan et al.. Cureus. 2023. Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review. doi:10.7759/cureus.46314 PubMed
[7] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
[8] Vincent I Lau et al.. Can J Anaesth. 2022. Health economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): a cost-effectiveness analysis. doi:10.1007/s12630-022-02335-9 PubMed
[9] Elie Akanny et al.. Int J Pharm. 2020. Development of enteric polymer-based microspheres by spray-drying for colonic delivery of Lactobacillus rhamnosus GG. doi:10.1016/j.ijpharm.2020.119414 PubMed
[10] Mario Baù et al.. Pediatr Gastroenterol Hepatol Nutr. 2020. Risk and Protective Factors for Gastrointestinal Symptoms associated with Antibiotic Treatment in Children: A Population Study. doi:10.5223/pghn.2020.23.1.35 PubMed
[11] Cecilia Mantegazza et al.. Pharmacol Res. 2018. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. doi:10.1016/j.phrs.2017.08.001 PubMed
[12] Valeria Agamennone et al.. BMC Gastroenterol. 2018. A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands. doi:10.1186/s12876-018-0831-x PubMed
[13] Jiayi Cai et al.. United European Gastroenterol J. 2018. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. doi:10.1177/2050640617736987 PubMed
[14] Ciro Esposito et al.. Probiotics Antimicrob Proteins. 2018. Frequency of Antibiotic-Associated Diarrhea and Related Complications in Pediatric Patients Who Underwent Hypospadias Repair: a Comparative Study Using Probiotics vs … doi:10.1007/s12602-017-9324-4 PubMed
[15] Donald Cameron et al.. World J Gastroenterol. 2017. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. doi:10.3748/wjg.v23.i45.7952 PubMed
[16] Hania Szajewska et al.. J Pediatr Gastroenterol Nutr. 2016. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. doi:10.1097/MPG.0000000000001081 PubMed
[17] Hania Szajewska et al.. Dig Dis. 2016. Probiotic Bacterial and Fungal Strains: Claims with Evidence. doi:10.1159/000443359 PubMed
[18] Sylvia Cruchet et al.. Paediatr Drugs. 2015. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. doi:10.1007/s40272-015-0124-6 PubMed
[19] Alfredo Guarino et al.. J Clin Gastroenterol. 2015. Probiotics for Prevention and Treatment of Diarrhea. doi:10.1097/MCG.0000000000000349 PubMed
[20] Danielle Barnes et al.. Nutr Clin Pract. 2015. Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. doi:10.1177/0884533615610081 PubMed
[21] Carlos Pérez. Nutr Hosp. 2015. [Probiotics for the treating acute diarrhea and preventing antibiotic-associated diarrhea in children]. doi:10.3305/nh.2015.31.sup1.8709 PubMed
[22] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed
[23] Alfredo Guarino et al.. Curr Opin Gastroenterol. 2009. Probiotics as prevention and treatment for diarrhea. doi:10.1097/MOG.0b013e32831b4455 PubMed
[24] Michael de Vrese et al.. Adv Biochem Eng Biotechnol. 2008. Probiotics, prebiotics, and synbiotics. doi:10.1007/10_2008_097 PubMed
[25] Michael de Vrese et al.. J Nutr. 2007. Probiotics and prebiotics: effects on diarrhea. doi:10.1093/jn/137.3.803S PubMed
[26] Lynne V McFarland. Am J Gastroenterol. 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. doi:10.1111/j.1572-0241.2006.00465.x PubMed
[27] Jeffry A Katz. J Clin Gastroenterol. 2006. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. doi:10.1097/00004836-200603000-00017 PubMed
[28] Riku Korhonen et al.. Inflammation. 2002. Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid. doi:10.1023/a:1019720701230 PubMed
[29] P R Marteau et al.. Am J Clin Nutr. 2001. Protection from gastrointestinal diseases with the use of probiotics. doi:10.1093/ajcn/73.2.430s PubMed
[30] R Korhonen et al.. Inflammation. 2001. Induction of nitric oxide synthesis by probiotic Lactobacillus rhamnosus GG in J774 macrophages and human T84 intestinal epithelial cells. doi:10.1023/a:1010971703271 PubMed
[31] J A Vanderhoof et al.. J Pediatr. 1999. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. doi:10.1016/s0022-3476(99)70053-3 PubMed
[32] T Arvola et al.. Pediatrics. 1999. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. doi:10.1542/peds.104.5.e64 PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.